BioSpace News Archive

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2021 of $0.85 per share on outstanding common stock.

BIOMODEX has announced the launch of Thrombotech™, a new hydrogel-based synthetic clot product that can be used for neurovascular training using EVIAS Plus™ - Biomodex’s innovative training solution for the treatment of ischemic stroke.

SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the third quarter of 2021 after market close on Monday, November 8, 2021.

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers Poster for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC)

Entasis Therapeutics today announced topline results from its ATTACK trial―a global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacterbaumannii.

PPD, Inc. will host a conference call on Thursday, October 28, 2021, at 8 a.m. (U.S. Eastern Time) to discuss its third quarter 2021 financial results.

Chemical Insights Research Institute of Underwriters Laboratories Inc. announced today that Christa Wright, PhD, has joined the team as Director of Toxicology to lead the organization’s efforts to expand its pollutant exposure laboratory and grow its toxicology health sciences program.

Lucid Diagnostics Inc. announced the closing on October 18, 2021 of its initial public offering of 5,000,000 shares of common stock at a price to the public of $14.00 per share for total gross proceeds of $70,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.

Cook Medical issued a global, voluntary recall of the Transseptal Needle and the Transseptal Needle with Catheter.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2021 financial results and operational highlights on Thursday, November 4, 2021, following the close of U.S. financial markets.